| Oct 25 |
Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent
|
| Oct 24 |
Dupixent® (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI
|
| Oct 24 |
The Zacks Analyst Blog Highlights Novo Nordisk, Novartis, Pfizer, Regeneron and Biogen
|
| Oct 23 |
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
|
| Oct 23 |
Amgen plans launch of Eylea biosimilar after court ruling
|
| Oct 23 |
The Zacks Analyst Blog Highlights Novo Nordisk, Novartis, Pfizer, Regeneron Pharmaceuticals and Biogen
|
| Oct 22 |
Regeneron drops after court rejects request for temporary injunction for Eylea generic
|
| Oct 22 |
Regeneron Pharmaceuticals' (NASDAQ:REGN) earnings growth rate lags the 26% CAGR delivered to shareholders
|
| Oct 22 |
5 Large Drug Stocks Likely to Outpace Q3 Earnings Estimates
|
| Oct 19 |
Regeneron announces three-year data for EYLEA HD Injection 8 mg study
|
